Exclusive: Third Rock's stealthy MOMA Therapeutics taps a longtime Millennium, Takeda vet as CEO
In the weeks after the Boston area first shut down for the pandemic, Asit Parikh picked up a phone and, dialing Takeda R&D chief Andy Plump, decided to end the 14-year-chapter that comprised almost the entirety of his professional career. Parikh joined Takeda in the 2008 Millennium Pharmaceuticals buyout; he led clinical studies on what would become the blockbuster Entyvio and since 2014 ran the Big Pharma’s GI division. But the pandemic had a way of making everyone take stock. “I always wanted big challenges,” he said. “It was time.”
Premium subscription required
Unlock this article along with other benefits by subscribing to one of our paid plans.